About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Torrent Pharmaceuticals Ltd.
Change Company
BSE Code
500420
ISIN Demat
INE685A01028
Book Value
240.61
NSE Code
TORNTPHARM
Dividend Yield %
0.91
Market Cap
1195423.14
P/E
60.68
EPS
58.21
Face Value
5
1 Week
1 Month
3 Months
6 Months
1 Year
10-Sep-2025
Torrent Pharmaceuticals enters into agreement to ...
02-Aug-2025
Torrent Pharmaceuticals informs about disclosure
29-Jul-2025
Torrent Pharmaceuticals soars on reporting 20% ri...
28-Jul-2025
Torrent Pharmaceuticals reports 20% rise in Q1 co...
28-Jul-2025
Torrent Pharmaceuticals informs about financial r...
21-Jul-2025
Allotment of Debentures
18-Jul-2025
Torrent Pharmaceuticals seeks CCI’s nod to acquir...
18-Jul-2025
Torrent Pharmaceuticals gains on seeking CCI’s no...
04-Jul-2025
Torrent Pharma executes SPA to acquire 2.41% stak...
04-Jul-2025
Torrent Pharma surges on executing SPA to acquire...
30-Jun-2025
Torrent Pharmaceuticals to acquire controlling st...
30-Jun-2025
Torrent Pharmaceuticals gains on inking pact to a...
30-Jun-2025
Torrent Pharmaceuticals informs about teleconfere...
27-Jun-2025
Torrent Pharmaceuticals raises Rs 300 crore throu...
27-Jun-2025
Torrent Pharmaceuticals surges on raising Rs 300 ...
Page
1
of
2
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.